Clinical trial · Interventional
Personalized DC Vaccine for Lung Cancer
Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer
NCT02956551CI-TRIAL-00033145SKLB1608unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DC vaccine | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- cell_therapy
- description
- tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
- interventionNames
- Biological: DC vaccine
Primary outcomes (1)
- measure
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- timeFrame
- 3 months after the last administration of cells
- description
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Secondary outcomes (1)
- measure
- objective response rate
- timeFrame
- through study completion, an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * pathologically confirmed non-small cell lung cancer * failed in previous standard chemotherapy and targeted therapy * anticipated life time \> 3month * Karnofsky performance status 0-1 * rehabilitate from previous therapy * adequate organ functions Exclusion Criteria: * mixed histological types * tumor emergency * abnormal coagulation condition * contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection * concomitant tumors * immunological co-morbidities
References
Publications (0)
Data not yet available
No reference posted for this study.